Akkad Holdings, LLC v. Trapollo, LLC

CourtDistrict Court, N.D. Georgia
DecidedDecember 16, 2021
Docket1:20-cv-04476
StatusUnknown

This text of Akkad Holdings, LLC v. Trapollo, LLC (Akkad Holdings, LLC v. Trapollo, LLC) is published on Counsel Stack Legal Research, covering District Court, N.D. Georgia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Akkad Holdings, LLC v. Trapollo, LLC, (N.D. Ga. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF GEORGIA ATLANTA DIVISION

Akkad Holdings, LLC,

Plaintiff,

v. Case No. 1:20-cv-4476-MLB

Trapollo, LLC, et al.,

Defendants.

________________________________/

OPINION & ORDER For the reasons set forth below, the Court grants Defendants Trapollo, LLC’s and Michael Braham’s motions to dismiss. (Dkts. 47; 48.) I. Background In May 2020, Plaintiff Akkad Holdings, LLC contacted Trapollo to purchase COVID-19 rapid tests and test kits. (Dkt. 42 ¶ 10.) Akkad inquired about the test quality and efficacy, pricing, governmental approvals, and general availability. (Id. ¶ 11.) Trapollo confirmed it could supply COVID-19 rapid tests and test kits to Akkad on the following terms:  Trapollo could supply Akkad with 150,000 COVID-19 test kits, with each kit containing 25 COVID-19 rapid tests and identified affiliated and associated items;  Pre-EUA approval, the sale price would be $25 per test kit;  Post-EUA approval, the sale price would be $34 per test kit; and  150,000 test kits containing 3,750,000 COVID-19 rapid tests were immediately available at the facilities of the manufacturer (“COVID-19 Test Purchase Terms”).1 (Id. ¶ 12.) Trapollo and its Chief Executive Officer (Braham) repeatedly confirmed Trapollo could immediately supply the 3.75 million tests identified in the fourth bullet of the COVID-19 Test Purchase Terms. (Id. ¶ 14.) Akkad asked whether the manufacturer had Emergency Use Authorization (“EUA”) from the Food and Drug Administration (“FDA”). (Id. ¶ 15.) Trapollo and Braham said the manufacturer’s application was pending. (Id. ¶ 16.) Based on these representations, Akkad signed a supply agreement on May 22,

2020 with Trapollo. (Id. ¶¶ 21–22.) The agreement included the COVID-19 Test Purchase Terms. (Id. ¶ 24.) Shortly after, Trapollo and Braham asked Akkad to pay more than

$1 million as a deposit, saying Trapollo would begin complying with its

1 “EUA” is the Emergency Use Authorization authority granted to the Food and Drug Administration (“FDA”). contractual obligations upon receipt of the money. (Id. ¶ 29.) Akkad did so. (Id. ¶ 30.) Akkad quickly learned the FDA had not granted the

manufacturer EUA approval and instead had placed the tests on a “Do Not Distribute” list. (Id. ¶ 31.) When confronted, Trapollo (through Braham) initially denied that had happened. (Id. ¶ 32.) Eventually,

however, they acknowledged the problem, provided some explanation for the difficulty, said the manufacturer was working with the FDA to obtain

the authorization, and assured Akkad the problem would be fixed in a “matter of days.” (Id. ¶¶ 33–34.) The promised “matter of days” turned into weeks. (Id. ¶ 35.) Akkad

eventually asked Trapollo and Braham to return its deposit and cancel the supply agreement. (Id.) Trapollo and Braham refused. (Id. ¶ 36.) They continued to assure Akkad that the problems would be fixed. (Id.)

Making the most of a bad situation, Akkad found a third party in Mexico that wanted to purchase COVID-19 rapid tests and entered into a purchase order with that company to supply 20 million tests. (Id. ¶ 37.)

Akkad then looked to Trapollo to supply the tests. Specifically, on July 1, 2021, Akkad asked Trapollo to provide the 3.75 million tests identified in the fourth bullet of the COVID-19 Test Purchase Terms. (Id. ¶ 38.) Braham raised several problems with doing so. He first said Trapollo had to check with the manufacturer about the availability of the test kits.

(Id. ¶ 40.) He also expressed concern about whether Trapollo could distribute tests on the FDA’s “Do Not Distribute” list. (Id. ¶ 42.) He then claimed Trapollo had to secure executive approval from the manufacturer

before releasing any tests but later said it actually had to get approval from an executive with the manufacturer’s parent company in Shanghai,

China. (Id. ¶¶ 43–44.) During all of this, he continued assuring Akkad the manufacturer had plenty of tests to satisfy Akkad’s purchase order with the Mexican customer. (Id. ¶ 45.)

Akkad quickly discovered Trapollo had not been honest. Specifically, it learned Trapollo never inquired with the manufacturer about the EUA approval status, the manufacturer never expected the

FDA to take its tests off the “Do Not Distribute” list, the manufacturer had no “parent company” in Shanghai, the manufacturer only had approximately 1.2 million COVID-19 rapid tests available for sale, and

the manufacturer never agreed to Trapollo’s price. (Id. ¶¶ 46–47.) All of this—of course—meant Trapollo could not supply the tests as required by the COVID-19 Test Purchase Terms, specifically as required by the fourth bullet which guaranteed immediate availability of 3.75 million tests.

Based on this alleged breach, Akkad again requested the return of its deposit and termination of the supply agreement. (Id. ¶ 49.) Trapollo again refused. (Id. ¶ 50.) Akkad demanded that Trapollo comply with

its obligations under the supply agreement, at least in part, by supplying the 1.2 million tests the manufacturer had available on the terms

specified in the supply agreement. (Id. ¶ 54.) Trapollo—perhaps not surprisingly given its track record—refused. (Id. ¶ 55.) On October 12, 2020, Akkad sent a letter to Trapollo stating, “Under the circumstances,

it is the intent of Akkad Holdings to formally rescind the [supply a]greement, and we hereby formally advise Trapollo of that election.” (Id. ¶ 68.)

Akkad sued Trapollo asserting eleven claims: breach of contract (Count I), money had and received (Count II), unjust enrichment (Count III), fraud in the inducement (Count IV), conversion (Count V),

conspiracy (Count VI), negligent misrepresentation (Count VII), mutual mistake/rescission (Count VIII), unilateral mistake/rescission (Count IX), punitive damages (Count X), and attorneys’ fees (Count XI). (Id. ¶¶ 69–112.) Akkad also sued Braham, asserting five causes of action: fraud in the inducement (Count IV), conspiracy (Count VI), negligent

misrepresentation (Count VII), punitive damages (Count X), and attorneys’ fees (Count XI). (Id. ¶¶ 81–86, 93–99, 108–12.) Trapollo seeks dismissal of all the claims against it except Counts I and XI. (Dkt. 47.)

Braham seeks dismissal of all five claims asserted against him. (Dkt. 48.)

II. Legal Standard A court may dismiss a pleading for “failure to state a claim upon which relief can be granted.” Fed. R. Civ. P. 12(b)(6). “At the motion to

dismiss stage, all well-pleaded facts are accepted as true, and the reasonable inferences therefrom are construed in the light most favorable to the plaintiff.” Bryant v. Avado Brands, Inc., 187 F.3d 1271, 1273 n.1

(11th Cir. 1999) (citing Hawthorne v. Mac Adjustment, Inc., 140 F.3d 1367, 1370 (11th Cir. 1998)). Even so, a complaint offering mere “labels and conclusions” or “a formulaic recitation of the elements of a cause of

action” is insufficient. Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (quoting Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007)). “To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to ‘state a claim to relief that is plausible

on its face.’” Id. (quoting Twombly, 550 U.S. at 570).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hawthorne v. Mac Adjustment, Inc.
140 F.3d 1367 (Eleventh Circuit, 1998)
Bryant v. Avado Brands, Inc.
187 F.3d 1271 (Eleventh Circuit, 1999)
Mann v. Taser International, Inc.
588 F.3d 1291 (Eleventh Circuit, 2009)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Bunch v. W.R. Grace & Co.
555 F.3d 1 (First Circuit, 2009)
Katrina Smith v. Ocwen Financial
488 F. App'x 426 (Eleventh Circuit, 2012)
Sean Barber v. America's Wholesale Lender
542 F. App'x 832 (Eleventh Circuit, 2013)
Holloman v. D. R. Horton, Inc.
524 S.E.2d 790 (Court of Appeals of Georgia, 1999)
Blockum v. Fieldale Farms Corp.
610 S.E.2d 82 (Court of Appeals of Georgia, 2005)
Reichman v. Southern Ear, Nose & Throat Surgeons, P.C.
598 S.E.2d 12 (Court of Appeals of Georgia, 2004)
Aliabadi v. McCar Development Corp.
547 S.E.2d 607 (Court of Appeals of Georgia, 2001)
Buckley v. Turner Heritage Homes, Inc.
547 S.E.2d 373 (Court of Appeals of Georgia, 2001)
Association Services, Inc. v. Smith
549 S.E.2d 454 (Court of Appeals of Georgia, 2001)
Pennington v. Braxley
480 S.E.2d 357 (Court of Appeals of Georgia, 1997)
Holmes v. Grubman
691 S.E.2d 196 (Supreme Court of Georgia, 2010)
Canales v. Wilson Southland Insurance Agency
583 S.E.2d 203 (Court of Appeals of Georgia, 2003)
First Data POS, Inc. v. Willis
546 S.E.2d 781 (Supreme Court of Georgia, 2001)
Orion Capital Partners, L. P. v. Westinghouse Electric Corp.
478 S.E.2d 382 (Court of Appeals of Georgia, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
Akkad Holdings, LLC v. Trapollo, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/akkad-holdings-llc-v-trapollo-llc-gand-2021.